Lung Cancer Diagnostics Market To Reach $23.31 Billion By 2033

August 2025 | Report Format: Electronic (PDF)

Lung Cancer Diagnostics Market Growth & Trends

The global lung cancer diagnostics market size is expected to reach USD 23.31 billion by 2033, registering a CAGR of 7.5% from 2025 to 2033, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.

key Request a free sample copy or view report summary: Lung Cancer Diagnostics Market Report

Lung Cancer Diagnostics Market Report Highlights

The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
EGFR mutation tests dominated the market with a 38.9% market share for 2024. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.
The hospitals and clinics segment dominated the market in 2024. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.
North America dominated the global lung cancer diagnostics market in 2024 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.